tiprankstipranks
Trending News
More News >
Hypera SA (HYPMY)
OTHER OTC:HYPMY

Hypera SA (HYPMY) Price & Analysis

Compare
9 Followers

HYPMY Stock Chart & Stats

$4.31
$0.02(0.65%)
At close: 4:00 PM EST
$4.31
$0.02(0.65%)

Hypera SA News

HYPMY FAQ

What was Hypera SA’s price range in the past 12 months?
Hypera SA lowest stock price was $3.21 and its highest was $5.19 in the past 12 months.
    What is Hypera SA’s market cap?
    Hypera SA’s market cap is $3.03B.
      When is Hypera SA’s upcoming earnings report date?
      Hypera SA’s upcoming earnings report date is Mar 12, 2026 which is in 36 days.
        How were Hypera SA’s earnings last quarter?
        Hypera SA released its earnings results on Oct 28, 2025. The company reported $0.133 earnings per share for the quarter, beating the consensus estimate of N/A by $0.133.
          Is Hypera SA overvalued?
          According to Wall Street analysts Hypera SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Hypera SA pay dividends?
            Hypera SA pays a Notavailable dividend of $0.036 which represents an annual dividend yield of 4.73%. See more information on Hypera SA dividends here
              What is Hypera SA’s EPS estimate?
              Hypera SA’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Hypera SA have?
              Hypera SA has 633,420,840 shares outstanding.
                What happened to Hypera SA’s price movement after its last earnings report?
                Hypera SA reported an EPS of $0.133 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.284%.
                  Which hedge fund is a major shareholder of Hypera SA?
                  Currently, no hedge funds are holding shares in HYPMY
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Hypera SA Stock Smart Score

                    3
                    Underperform
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10

                    Technicals

                    SMA
                    Positive
                    20 days / 200 days
                    Momentum
                    43.89%
                    12-Months-Change

                    Fundamentals

                    Return on Equity
                    6.57%
                    Trailing 12-Months
                    Asset Growth
                    0.73%
                    Trailing 12-Months

                    Company Description

                    Hypera SA

                    Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.

                    Hypera SA (HYPMY) Earnings & Revenues

                    HYPMY Company Deck

                    HYPMY Earnings Call

                    Q3 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The earnings call highlighted significant achievements, including strong revenue growth, successful working capital optimization, and record operational cash flow. However, challenges were noted in the institutional market and R&D approval delays. Despite these challenges, the overall performance and strategic initiatives indicate a positive outlook.View all HYPMY earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Perrigo Company
                    Supernus Pharmaceuticals
                    ANI Pharmaceuticals
                    Indivior
                    Amneal Pharmaceuticals

                    Ownership Overview

                    <0.01%0.03%99.97%
                    Insiders
                    0.03% Other Institutional Investors
                    99.97% Public Companies and
                    Individual Investors

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks